Orforglipron for adults who are overweight and at risk of obesity-related health problems
Tests orforglipron against placebo in adults who are overweight.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Key facts
- Where
- Ansan-si, Anyang-si, Busan, Guri-si, Gwangju, Junggu, Seogu, Seongnam, Seongnam-si, and Seoul, South KoreaSee the 12 sites
- Phase
- Phase 3
Where in South Korea
- Korea University Ansan HospitalAnsan-si, South KoreaNot yet recruiting
- Hallym University Sacred Heart HospitalAnyang-si, South KoreaNot yet recruiting
- Pusan National University Yangsan HospitalBusan, South KoreaNot yet recruiting
- Hanyang University Guri HospitalGuri-si, South KoreaNot yet recruiting
- Chosun University HospitalGwangju, South KoreaNot yet recruiting
- Kyungpook National University HospitalJunggu, South KoreaNot yet recruiting
- Konyang University HospitalSeogu, South KoreaNot yet recruiting
- Seoul National University Bundang HospitalSeongnam, South KoreaNot yet recruiting
- CHA Bundang Medical Center, CHA UniversitySeongnam-si, South KoreaNot yet recruiting
- Hanyang University Seoul HospitalSeoul, South KoreaNot yet recruiting
- Korea University Anam HospitalSeoul, South KoreaNot yet recruiting
- Seoul National University HospitalSeoul, South KoreaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07794579EU 2026-526175-35-00
- Record updated
- 5 November 2026
- Original description
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.Read full original descriptionShow less
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Individuals With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
Inclusion: Have an increased waist-to-height ratio of ≥0.5; Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia); Have at least one unsuccessful attempt to reduce body weight based on diet and exercise; Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds.
Exclusion: Do not have a stable body weight within 90 days before screening; Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening; Have a prior or planned surgical treatment or procedure for obesity; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold); Have hypertension or history of hypertension; Have dyslipidemia or history of dyslipidemia.